Potential role of 18 F-2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography imaging in patients presenting with generalized lymphadenopathy

Indian Journal of Nuclear Medicine

Volumn 30, Issue 1, 2015, Pages 31-38

  Karunanithi, Sellam ^a   Kumar, Ganesh ^a   Sharma, Punit ^a   Bal, Chandrasekhar ^a   Kumar, Rakesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

18 F 2 fluoro 2 deoxy glucose positron emission tomography computed tomography; generalized lymphadenopathy; lymphoma; sarcoidosis; tuberculosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACTINOMYCOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B CELL LYMPHOMA; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENERALIZED LYMPHADENOPATHY; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; IMMUNOBLASTIC LYMPHADENOPATHY; METASTASIS; NONHODGKIN LYMPHOMA; REVIEW; SARCOIDOSIS; SINUS HISTIOCYTOSIS; T CELL LYMPHOMA; TUBERCULOSIS;

EID: 84920280281     PISSN: 09723919     EISSN: 09740244     Source Type: Journal    
DOI: 10.4103/0972-3919.147532     Document Type: Review

References (52)

1. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Review of the entity. Semin Diagn Pathol 1990;7:19-73.
2. Karunanithi S, Singh H, Sharma P, Naswa N, Kumar R 18F-FDG PET/CT imaging features of Rosai Dorfman disease: A rare cause of massive generalized lymphadenopathy. Clin Nucl Med 2014;39:268-9.
3. Raveenthiran V, Dhanalakshmi M, Hayavadana Rao PV, Viswanathan P. Rosai-Dorfman disease: Report of a 3-year-old girl with critical review of treatment options. Eur J Pediatr Surg 2003;13:350-4.
4. Deshayes E, Le Berre JP, Jouanneau E, Vasiljevic A, Raverot G, Seve P 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med 2013;38:e50-2.
5. Huang JY, Lu CC, Hsiao CH, Tzen KY. FDG PET/CT findings in purely cutaneous Rosai-Dorfman disease. Clin Nucl Med 2011;36:e13-5.
6. Tsang JS, Anthony MP, Wong MP, Wong CS. The use of FDG-PET/CT in extranodal Rosai-Dorfman disease of bone. Skeletal Radiol 2012;41:715-7.
7. Perera AS, Keleher AJ, Nath M. Rosai-Dorfman disease presenting as a male breast mass. Am Surg 2007;73:294-5.
8. Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. Korean J Hematol 2012;47:163-77.
9. Elboga U, Narin Y, Urhan M, Sahin E. FDG PET/CT appearance of multicentric Castleman's disease mimicking lymphoma. Rev Esp Med Nucl Imagen Mol 2012;31:142-4.
10. Shin DY, Jeon YK, Hong YS, Kim TM, Lee SH, Kim DW, et al. Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 2011;52:1517-22.
11. Enomoto K, Nakamichi I, Hamada K, Inoue A, Higuchi I, Sekimoto M, et al. Unicentric and multicentric Castleman's disease. Br J Radiol 2007;80:e24-6.
12. Lee ES, Paeng JC, Park CM, Chang W, Lee WW, Kang KW, et al. Metabolic characteristics of Castleman disease on 18F-FDG PET in relation to clinical implication. Clin Nucl Med 2013;38:339-42.
13. Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M, et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur J Nucl Med Mol Imaging 2009;36:648-52.
14. Jain V, Hasselquist S, Delaney MD. PET scanning in sarcoidosis. Ann N Y Acad Sci 2011;1228:46-58.
15. Soussan M, Augier A, Brillet PY, Weinmann P, Valeyre D. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med 2014;39:e146-59.
16. Aide N, Allouache D, Ollivier Y, de Raucourt S, Switsers O, Bardet S. Early 2'-deoxy-2'-[18F] fluoro-D-glucose PET metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like lesions. Mol Imaging Biol 2009;11:224-8.
17. Perlman DC, D'Amico R, Salomon N. Mycobacterial Infections of the head and neck. Curr Infect Dis Rep 2001;3:233-41.
18. Geldmacher H, Taube C, Kroeger C, Magnussen H, Kirsten DK. Assessment of lymph node tuberculosis in northern Germany: A clinical review. Chest 2002;121:1177-82.
19. Kim HW, Choi BW, Won KS, Zeon SK. Cervical tuberculous lymphadenitis mimicking distant lymph node metastasis on F-18 FDG PET/CT in a patient with gastric carcinoid tumor. Clin Nucl Med 2009;34:946-7.
20. Sathekge M, Maes A, Van de Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med 2013;43:349-66.
21. Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 2009;36:632-9.
22. Han JY, Lee KN, Lee JK, Kim YH, Choi SJ, Jeong YJ, et al. An overview of thoracic actinomycosis: CT features. Insights Imaging 2013;4:245-52.
23. Bartlett AH, Rivera AL, Krishnamurthy R, Baker CJ. Thoracic actinomycosis in children: Case report and review of the literature. Pediatr Infect Dis J 2008;27:165-9.
24. Webb WR, Sagel SS. Actinomycosis involving the chest wall: CT findings. AJR Am J Roentgenol 1982;139:1007-9.
25. Amrikachi M, Krishnan B, Finch CJ, Shahab I. Actinomyces and actinobacillus actinomycetemcomitans-actinomyces-associated lymphadenopathy mimicking lymphoma. Arch Pathol Lab Med 2000;124:1502-5.
26. Mok GS, Choi FP, Chu WC. Actinomycosis imitating parotid cancer with metastatic lymph nodes in FDG PET/CT. Clin Nucl Med 2011;36:309-10.
27. Mansoor CA, Bhargavan PV, Rajanish R, Nair LR. Disseminated histoplasmosis. Indian J Orthop 2013;47:639-42.
28. Aidé MA. Chapter 4-Histoplasmosis. J Bras Pneumol 2009;35:1145-51.
29. Antonello VS, Zaltron VF, Vial M, Oliveira FM, Severo LC. Oropharyngeal histoplasmosis: Report of eleven cases and review of the literature. Rev Soc Bras Med Trop 2011;44:26-9.
30. Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002;36:297-301.
31. Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest 2012;122:3439-47.
32. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50 Suppl 1:21S-30.
33. Ömür Ö, Baran Y, Oral A, Ceylan Y. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Diagn Interv Radiol 2014;20:185-92.
34. Tohda S. Overview of lymphoid neoplasms in the fourth edition of the WHO classification. Rinsho Byori 2012;60:560-4.
35. Hosein PJ, Lossos IS. The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma. European J Clin Med Oncol 2010;2:131-38.
36. Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 2013;122:61-7.
37. Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol 2014;164:315-28.
38. Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, et al. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011;47:1312-8.
39. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18) F-FDG avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med 2010;51:25-30.
40. Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, et al. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2014;55:2079-84.
41. Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995;13:1726-33.
42. Armitage JO. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 2013;88:910-8.
43. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-75.
44. Casulo C, Schöder H, Feeney J, Lim R, Maragulia J, Zelenetz AD, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma 2013;54:2163-7.
45. Cheng J, Yang XY, Xu WG, Song XY, Dai D, Zhu YJ. Clinical significance of (18) F-FDG PET/CT evaluation of response to treatment in T-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi 2012;33:16-9.
46. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. N Engl J Med 1975;292:1-8.
47. Brown JR, Skarin AT. Clinical mimics of lymphoma. Oncologist 2004;9:406-16.
48. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010;148:673-89.
49. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007;109:292-9.
50. Nishiyama Y, Yamamoto Y, Kimura N, Ishikawa S, Sasakawa Y, Ohkawa M. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer. Ann Nucl Med 2008;22:245-50.
51. Joshi P, Lele V. Prostatic adenocarcinoma masquerading as generalized lymphadenopathy and mimicking lymphoma on FDG PET/CT: Diagnosis, staging, and evaluation of therapy response by FDG PET/CT. Nephrourol Mon 2012;4:482-4.
52. Yune S, Jang KT, Jung SM, Kim JH, Lee J. Generalized lymphadenopathy mimicking malignant lymph node metastases after interferon-a2b therapy for melanoma. Melanoma Res 2013;23:336-9.